With all eyes on their Covid-19 drug, Regeneron wins a landmark approval in Ebola
For the first time, the FDA has approved a therapy for Ebola, handing a landmark OK to Regeneron at the same moment that the New York biotech awaits word from the agency on a similar drug they developed for Covid-19.
Regeneron developed the drug, a cocktail of 3 neutralizing Ebola antibodies now known as Inmazeb, during the 2014-2016 West African outbreak, and when cases rose again in the DRC in 2018, the NIH selected it as one of four drugs to be tested in a large, first-of-its-kind clinical trial. The study was halted 12 months later after two drugs showed overwhelming efficacy. About a third of Ebola patients who received the Regeneron drug died, compared with just over 50% for the antibody ZMapp.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.